NEWS
Zylera Pharmaceuticals Introduces FOLMOR to the Trade
October 30, 2006
Research Triangle Park, North Carolina – October 30, 2006 - Zylera Pharmaceuticals announced today the availability of FOLMOR™ (folic acid 2.5mg, B6 25mg, B12 2mg and primorine 875mg) for the treatment of cardiovascular disease.
“We are excited to announce the introduction of FOLMOR, our novel, proprietary prescription product for the treatment of cardiovascular disease, the leading cause of death in the United States,” said Dr. Philip Tabbiner, chief executive officer of Zylera Pharmaceuticals. “We believe that FOLMOR will address elevated homocysteine levels, one of the many controllable risk factors associated with the development of cardiovascular disease.” FOLMOR breaks down homocysteine in the body and may reduce the risk of cardiovascular disease.
There are several, controllable risk factors associated with the development of cardiovascular disease. High cholesterol and elevated levels of homocysteine, an amino acid found in the blood, are two of these risk factors. According to the American Heart Association, there are approximately 71.3 million people in the United States who have one or more forms of cardiovascular disease. Cardiovascular disease is the leading cause of death for men and women in the United States.
About FOLMOR
FOLMOR, a new treatment from Zylera, breaks down homocysteine in the body. Patients benefit from the dual effect of folic acid, combined with Zylera’s Cytac™ technology, thus reducing the risk of developing cardiovascular disease. Cytac, a novel carbonyl-trapping agent, enables Zylera’s products to react with, or “trap,” toxic carbonyl groups such as aldehydes and ketones that the body produces under conditions of oxidative stress to form less-harmful derivatives that are then eliminated through the kidneys.
About Zylera Pharmaceuticals
Zylera is a specialty pharmaceutical company focused on developing medications that will treat multiple diseases arising within the inflammation and immunosuppressive pathways. Its near-term pipeline includes products for diabetes, elevated cholesterol, osteoporosis, and osteoarthritis, utilizing proprietary and patented chemical entities designed to restore key metabolic processes. Chief among these is Cytac, a carbonyl-trapping agent. Zylera is based in Research Triangle Park, NC.
FOR IMMEDIATE RELEASE Media Contact:
Susan Preston, TRx Pharma
Office: (919) 313-3568